In the 2024 election, seven out of 10 states passed ballot measures protecting abortion rights. But the effects won't be seen immediately, experts say.
A panel of experts at the HLTH conference agreed that states with strict abortion measures are likely to see negative economic impact as medical residents decline to train there and physicians move out.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Research shows that medical residents of all specialties are avoiding states that ban abortion. This was discussed during a panel discussion at Engage at HLTH on Sunday in Las Vegas.
In this episode, we’re joined by Rabia Muqaddam, senior staff attorney at the Center for Reproductive Rights. Muqaddam discusses the Supreme Court's recent decision that preserved access to the abortion pill mifepristone.
The Supreme Court made several recent decisions that impact healthcare, including overturning the Chevron deference and upholding access to the abortion pill mifepristone.
Only 8% of large employers have reduced or expanded their coverage for abortion after the Dobbs v. Jackson decision, a new report from KFF found.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Representatives from the Guttmacher Institute and NFPRHA shared their wins and losses for reproductive health in 2023. Their wins include states moving to protect contraception and the approval of Opill, while their losses include state enactments of abortion bans and the lack of funding for Title X.
Opposing sides are girding for a likely momentous constitutional confrontation.
Annual family premiums for employer-sponsored coverage reached $23,968 in 2023, according to a new KFF survey. Of that family premium total, workers are contributing $6,575 annually.
New York City-based Hey Jane, a virtual abortion provider, announced last week that it is now offering vaginal infections treatment. This includes treatment for urinary tract infections, bacterial vaginosis and herpes. It is also offering birth control and emergency contraception.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Health insurers can support the fight for reproductive health rights by improving their benefits and using their power to enact change with lawmakers, said Alexis McGill Johnson, president and CEO of Planned Parenthood Federation of America and the Planned Parenthood Action Fund. She made these comments at the AHIP 2023 conference in Portland.
If a drug’s FDA approval could be overturned by any judge, anywhere, anytime the pharmaceutical industry would be severely impacted. While mifepristone is no blockbuster, a legal precedent allowing courts to overturn the FDA’s approval could be applied to other drugs like blockbuster drugs like Viagra, Humira, or the new diabetes, weight-loss drugs Ozempic or Wegovy.
The quest to enact local bans has become particularly acute in small towns, like West Wendover, Nevada, and Hobbs, New Mexico, which are situated by borders between states that have restricted abortion and states where laws preserve access.
Mifepristone and misoprostol, two pills that are taken together to terminate a pregnancy, have been approved by the FDA since 2000. But access to these drugs have been in serious jeopardy this year, and a federal judge in Texas recently ruled to suspend the FDA's decadeslong approval of mifepristone. The final outcome for abortion pill access in the U.S. is still unclear among confliction federal rulings — the issue will likely end up in the Supreme Court.
Patient privacy is evolving rapidly in the post-Dobbs era, according to healthcare and life science lawyers in a webinar hosted by the American Bar Association on Wednesday.